FPC
PRTK

Falcon Point Capital’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Falcon Point Capital’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-113,415
Closed -$2.03M – 127
2017
Q4 		$2.03M Sell
113,415
-32,364
-22% -$675K 0.34% 50
2017
Q3 		$3.12M Buy
145,779
+121,796
+508% +$2.83M 0.45% 47
2017
Q2 		$578K Buy
23,983
+13,597
+131% +$301K 0.08% 99
2017
Q1 		$200K Buy
+10,386
New +$164K 0.03% 113

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Falcon Point Capital's PRTK Position: Q1 2018 in Review

Falcon Point Capital sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2018, closing a stake of 113,415 shares — an estimated $2.03M sold.

Falcon Point Capital first reported a position in PRTK in Q1 2017 and held it in 4 quarters. The position peaked at $3.12M in Q3 2017. 114 funds tracked by Wall St. Rank hold PRTK as of Q1 2018.

  • Falcon Point Capital reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Falcon Point Capital sold 113,415 Paratek Pharmaceuticals, Inc. shares in Q1 2018, an estimated $2.03M.
  • Falcon Point Capital first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2017 and held it in 4 quarters.
  • Falcon Point Capital's Paratek Pharmaceuticals, Inc. position peaked at $3.12M in Q3 2017.
  • 114 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2018.

Based on Falcon Point Capital's 13F filing for Q1 2018, filed 26 Apr 2018.